{"id":516463,"date":"2021-07-22T09:03:14","date_gmt":"2021-07-22T13:03:14","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/trial-launches-to-evaluate-glycomimetics-uproleselan-added-to-cladribine-plus-low-dose-cytarabine-in-aml-patients\/"},"modified":"2021-07-22T09:03:14","modified_gmt":"2021-07-22T13:03:14","slug":"trial-launches-to-evaluate-glycomimetics-uproleselan-added-to-cladribine-plus-low-dose-cytarabine-in-aml-patients","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/trial-launches-to-evaluate-glycomimetics-uproleselan-added-to-cladribine-plus-low-dose-cytarabine-in-aml-patients\/","title":{"rendered":"Trial Launches to Evaluate GlycoMimetics\u2019 Uproleselan Added to Cladribine Plus Low-Dose Cytarabine in AML Patients"},"content":{"rendered":"<p>        <!--.bwalignc { text-align: center; list-style-position: inside }body {font:normal small Arial,Helvetica,sans-serif;color:#000;background-color:#fff;padding:24px;margin:0;} a img {border:0;} h3 {font-size:medium;color:#000;margin:0 0 1em 0; text-align:center;}-->  <\/p>\n<p class=\"bwalignc\"><b>Trial Launches to Evaluate GlycoMimetics\u2019 Uproleselan Added to Cladribine Plus Low-Dose Cytarabine in AML Patients<\/b><\/p>\n<p class=\"bwalignc\"><i>Trial to study uproleselan combination in patients with high-risk treated secondary AML <\/i><\/p>\n<p>ROCKVILLE, Md.&#8211;(<a href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;<br \/>\nGlycoMimetics, Inc. (Nasdaq: GLYC) announced today that clinicians have treated the first patient in a Phase 1b\/2 study evaluating the company\u2019s lead drug candidate, uproleselan, added to cladribine plus low dose cytarabine (LDAC) in patients with treated secondary AML (ts-AML). The investigator-sponsored trial is being led by Tapan Kadia, M.D., associate professor of Leukemia at The University of Texas MD Anderson Cancer Center.\n<\/p>\n<p>\nAccording to Eric Feldman, M.D., GlycoMimetics\u2019 Chief Medical Officer, \u201cPatients with treated secondary AML have an extremely poor prognosis. Despite new drug approvals in the field, subgroups of patients with limited options still exist, especially those whose disease has progressed following treatment with a hypomethylating agent. Our previous preclinical and clinical research supports the potential for these patients to benefit from the addition of uproleselan. If the new study demonstrates that targeting E-selectin with uproleselan could help to overcome resistance to other therapies, this would be a significant achievement that underscores the broad potential of our drug candidate.\u201d\n<\/p>\n<p><b>About the Phase 1b\/2 Clinical Trial<\/b><\/p>\n<p>\nThe Phase 1b\/2 single-arm trial is enrolling patients 18 years or older, with a diagnosis of ts-AML who have not received therapy for their AML. Considered a distinct high-risk subset of AML with an adverse prognosis, ts-AML is defined as AML arising from a previously treated antecedent myeloid neoplasm (myelodysplastic syndrome or myeloproliferative neoplasm). Clinicians plan to enroll approximately 25 patients in the trial.\n<\/p>\n<p>\nGlycoMimetics is providing uproleselan for the investigator-sponsored trial. The study is designed to evaluate both the safety and tolerability of the combination therapy, as well as to identify a recommended Phase 2 dose of the uproleselan triple combination approach in patients with ts-AML. Among the trial\u2019s secondary objectives are efficacy assessments including overall response rate, complete response, complete response without blood count recovery, and other measures. The rate of minimal residual disease negativity will also be evaluated by flow cytometry at response. Exploratory endpoints include examination of biomarkers of response and resistance and the correlation of the expression of E-selectin ligand-forming glycosylation genes of leukemic blasts with clinical outcome.\n<\/p>\n<p><b>About Uproleselan<\/b><\/p>\n<p>\nDiscovered and developed by GlycoMimetics, uproleselan is an investigational, first-in-class, targeted antagonist of E-selectin. Uproleselan (yoo\u2019 pro le\u2019 sel an), currently in a comprehensive Phase 3 development program in AML, has received Breakthrough Therapy designation from the U.S. Food and Drug Administration and the Chinese Health authority for the treatment of adult AML patients with relapsed or refractory disease. Uproleselan is designed to block E-selectin (an adhesion molecule on cells in the bone marrow) from binding with blood cancer cells as a targeted approach to disrupting well-established mechanisms of leukemic cell resistance\n<\/p>\n<p><b>About GlycoMimetics, Inc.<\/b><\/p>\n<p>\nGlycoMimetics is a clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers, including acute myeloid leukemia (AML), and for inflammatory diseases with high unmet need. The Company\u2019s science is based on an understanding of the role that carbohydrates play on the surface of every living cell and applying its specialized chemistry platform to discover small molecule drugs, known as glycomimetics, that alter these carbohydrate-mediated pathways in a variety of disease states, including signaling in cancer and inflammation. As a leader in this space, GlycoMimetics is leveraging this unique targeted approach to advance its pipeline of wholly owned drug candidates, with the goal of developing transformative therapies for serious diseases. The Company\u2019s leading drug candidate, uproleselan, has received Breakthrough Therapy Designation in the U.S. and China and is undergoing evaluation across a range of patient populations, including a Phase 3 trial in relapsed\/refractory AML. GlycoMimetics is located in Rockville, MD in the BioHealth Capital Region. Learn more at <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.glycomimetics.com&amp;esheet=52464522&amp;newsitemid=20210722005600&amp;lan=en-US&amp;anchor=www.glycomimetics.com&amp;index=1&amp;md5=bb0cef47bf159984fd492f4d01e324e1\">www.glycomimetics.com<\/a>.\n<\/p>\n<p><b>Forward-Looking Statements<\/b><\/p>\n<p>\nThis press release contains forward-looking statements. These forward-looking statements include those relating to the planned or potential clinical development and potential benefits and impact of the Company\u2019s drug candidate, uproleselan. Actual results may differ materially from those described in these forward-looking statements. For a further description of the risks associated with these statements, as well as other risks facing GlycoMimetics, please see the risk factors described in the Company\u2019s annual report on Form 10-K filed with the U.S. Securities and Exchange Commission (SEC) on February 28, 2021, and other filings GlycoMimetics makes with the SEC from time to time. Forward-looking statements speak only as of the date of this release, and GlycoMimetics undertakes no obligation to update or revise these statements, except as may be required by law.\n<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210722005600r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\" \/><span class=\"bwct31415\" \/><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">View source version on businesswire.com: <\/span><span id=\"mmgallerylink-link\"><a href=\"https:\/\/www.businesswire.com\/news\/home\/20210722005600\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20210722005600\/en\/<\/a><\/span><\/p>\n<p>\nInvestor Contact:<br \/>\n<br \/>Shari Annes<br \/>\n<br \/>Phone: 650-888-0902<br \/>\n<br \/>Email: <a rel=\"nofollow\" href=\"mailto:sannes@annesassociates.com\">sannes@annesassociates.com<\/a><\/p>\n<p>\nMedia Contact:<br \/>\n<br \/>Jamie Lacey-Moreira<br \/>\n<br \/>Phone: 410-299-3310<br \/>\n<br \/>Email: <a rel=\"nofollow\" href=\"mailto:jamielacey@presscommpr.com\">jamielacey@presscommpr.com<\/a><\/p>\n<p><b>KEYWORDS:<\/b> United States North America Maryland<\/p>\n<p><b>INDUSTRY KEYWORDS:<\/b> Biotechnology Health Pharmaceutical Clinical Trials Oncology<\/p>\n<p><b>MEDIA:<\/b><\/p>\n<table cellpadding=\"3\" cellspacing=\"3\">\n<tr>\n<td><font face=\"Arial\" size=\"2\"><b>Logo<\/b><\/font><\/td>\n<\/tr>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20210722005600\/en\/893363\/3\/Logo-Glyco.jpg\" alt=\"Logo\" \/><\/td>\n<\/tr>\n<tr>\n<td><font face=\"Arial\" size=\"2\"><\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"<p>Trial Launches to Evaluate GlycoMimetics\u2019 Uproleselan Added to Cladribine Plus Low-Dose Cytarabine in AML Patients Trial to study uproleselan combination in patients with high-risk treated secondary AML ROCKVILLE, Md.&#8211;(BUSINESS WIRE)&#8211; GlycoMimetics, Inc. (Nasdaq: GLYC) announced today that clinicians have treated the first patient in a Phase 1b\/2 study evaluating the company\u2019s lead drug candidate, uproleselan, added to cladribine plus low dose cytarabine (LDAC) in patients with treated secondary AML (ts-AML). The investigator-sponsored trial is being led by Tapan Kadia, M.D., associate professor of Leukemia at The University of Texas MD Anderson Cancer Center. According to Eric Feldman, M.D., GlycoMimetics\u2019 Chief Medical Officer, \u201cPatients with treated secondary AML have an extremely poor prognosis. Despite new drug approvals in the field, subgroups &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/trial-launches-to-evaluate-glycomimetics-uproleselan-added-to-cladribine-plus-low-dose-cytarabine-in-aml-patients\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Trial Launches to Evaluate GlycoMimetics\u2019 Uproleselan Added to Cladribine Plus Low-Dose Cytarabine in AML Patients&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-516463","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Trial Launches to Evaluate GlycoMimetics\u2019 Uproleselan Added to Cladribine Plus Low-Dose Cytarabine in AML Patients - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/trial-launches-to-evaluate-glycomimetics-uproleselan-added-to-cladribine-plus-low-dose-cytarabine-in-aml-patients\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Trial Launches to Evaluate GlycoMimetics\u2019 Uproleselan Added to Cladribine Plus Low-Dose Cytarabine in AML Patients - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Trial Launches to Evaluate GlycoMimetics\u2019 Uproleselan Added to Cladribine Plus Low-Dose Cytarabine in AML Patients Trial to study uproleselan combination in patients with high-risk treated secondary AML ROCKVILLE, Md.&#8211;(BUSINESS WIRE)&#8211; GlycoMimetics, Inc. (Nasdaq: GLYC) announced today that clinicians have treated the first patient in a Phase 1b\/2 study evaluating the company\u2019s lead drug candidate, uproleselan, added to cladribine plus low dose cytarabine (LDAC) in patients with treated secondary AML (ts-AML). The investigator-sponsored trial is being led by Tapan Kadia, M.D., associate professor of Leukemia at The University of Texas MD Anderson Cancer Center. According to Eric Feldman, M.D., GlycoMimetics\u2019 Chief Medical Officer, \u201cPatients with treated secondary AML have an extremely poor prognosis. Despite new drug approvals in the field, subgroups &hellip; Continue reading &quot;Trial Launches to Evaluate GlycoMimetics\u2019 Uproleselan Added to Cladribine Plus Low-Dose Cytarabine in AML Patients&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/trial-launches-to-evaluate-glycomimetics-uproleselan-added-to-cladribine-plus-low-dose-cytarabine-in-aml-patients\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-07-22T13:03:14+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210722005600r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/trial-launches-to-evaluate-glycomimetics-uproleselan-added-to-cladribine-plus-low-dose-cytarabine-in-aml-patients\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/trial-launches-to-evaluate-glycomimetics-uproleselan-added-to-cladribine-plus-low-dose-cytarabine-in-aml-patients\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Trial Launches to Evaluate GlycoMimetics\u2019 Uproleselan Added to Cladribine Plus Low-Dose Cytarabine in AML Patients\",\"datePublished\":\"2021-07-22T13:03:14+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/trial-launches-to-evaluate-glycomimetics-uproleselan-added-to-cladribine-plus-low-dose-cytarabine-in-aml-patients\\\/\"},\"wordCount\":832,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/trial-launches-to-evaluate-glycomimetics-uproleselan-added-to-cladribine-plus-low-dose-cytarabine-in-aml-patients\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20210722005600r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/trial-launches-to-evaluate-glycomimetics-uproleselan-added-to-cladribine-plus-low-dose-cytarabine-in-aml-patients\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/trial-launches-to-evaluate-glycomimetics-uproleselan-added-to-cladribine-plus-low-dose-cytarabine-in-aml-patients\\\/\",\"name\":\"Trial Launches to Evaluate GlycoMimetics\u2019 Uproleselan Added to Cladribine Plus Low-Dose Cytarabine in AML Patients - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/trial-launches-to-evaluate-glycomimetics-uproleselan-added-to-cladribine-plus-low-dose-cytarabine-in-aml-patients\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/trial-launches-to-evaluate-glycomimetics-uproleselan-added-to-cladribine-plus-low-dose-cytarabine-in-aml-patients\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20210722005600r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"datePublished\":\"2021-07-22T13:03:14+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/trial-launches-to-evaluate-glycomimetics-uproleselan-added-to-cladribine-plus-low-dose-cytarabine-in-aml-patients\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/trial-launches-to-evaluate-glycomimetics-uproleselan-added-to-cladribine-plus-low-dose-cytarabine-in-aml-patients\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/trial-launches-to-evaluate-glycomimetics-uproleselan-added-to-cladribine-plus-low-dose-cytarabine-in-aml-patients\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20210722005600r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20210722005600r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/trial-launches-to-evaluate-glycomimetics-uproleselan-added-to-cladribine-plus-low-dose-cytarabine-in-aml-patients\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Trial Launches to Evaluate GlycoMimetics\u2019 Uproleselan Added to Cladribine Plus Low-Dose Cytarabine in AML Patients\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Trial Launches to Evaluate GlycoMimetics\u2019 Uproleselan Added to Cladribine Plus Low-Dose Cytarabine in AML Patients - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/trial-launches-to-evaluate-glycomimetics-uproleselan-added-to-cladribine-plus-low-dose-cytarabine-in-aml-patients\/","og_locale":"en_US","og_type":"article","og_title":"Trial Launches to Evaluate GlycoMimetics\u2019 Uproleselan Added to Cladribine Plus Low-Dose Cytarabine in AML Patients - Market Newsdesk","og_description":"Trial Launches to Evaluate GlycoMimetics\u2019 Uproleselan Added to Cladribine Plus Low-Dose Cytarabine in AML Patients Trial to study uproleselan combination in patients with high-risk treated secondary AML ROCKVILLE, Md.&#8211;(BUSINESS WIRE)&#8211; GlycoMimetics, Inc. (Nasdaq: GLYC) announced today that clinicians have treated the first patient in a Phase 1b\/2 study evaluating the company\u2019s lead drug candidate, uproleselan, added to cladribine plus low dose cytarabine (LDAC) in patients with treated secondary AML (ts-AML). The investigator-sponsored trial is being led by Tapan Kadia, M.D., associate professor of Leukemia at The University of Texas MD Anderson Cancer Center. According to Eric Feldman, M.D., GlycoMimetics\u2019 Chief Medical Officer, \u201cPatients with treated secondary AML have an extremely poor prognosis. Despite new drug approvals in the field, subgroups &hellip; Continue reading \"Trial Launches to Evaluate GlycoMimetics\u2019 Uproleselan Added to Cladribine Plus Low-Dose Cytarabine in AML Patients\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/trial-launches-to-evaluate-glycomimetics-uproleselan-added-to-cladribine-plus-low-dose-cytarabine-in-aml-patients\/","og_site_name":"Market Newsdesk","article_published_time":"2021-07-22T13:03:14+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210722005600r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/trial-launches-to-evaluate-glycomimetics-uproleselan-added-to-cladribine-plus-low-dose-cytarabine-in-aml-patients\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/trial-launches-to-evaluate-glycomimetics-uproleselan-added-to-cladribine-plus-low-dose-cytarabine-in-aml-patients\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Trial Launches to Evaluate GlycoMimetics\u2019 Uproleselan Added to Cladribine Plus Low-Dose Cytarabine in AML Patients","datePublished":"2021-07-22T13:03:14+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/trial-launches-to-evaluate-glycomimetics-uproleselan-added-to-cladribine-plus-low-dose-cytarabine-in-aml-patients\/"},"wordCount":832,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/trial-launches-to-evaluate-glycomimetics-uproleselan-added-to-cladribine-plus-low-dose-cytarabine-in-aml-patients\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210722005600r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/trial-launches-to-evaluate-glycomimetics-uproleselan-added-to-cladribine-plus-low-dose-cytarabine-in-aml-patients\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/trial-launches-to-evaluate-glycomimetics-uproleselan-added-to-cladribine-plus-low-dose-cytarabine-in-aml-patients\/","name":"Trial Launches to Evaluate GlycoMimetics\u2019 Uproleselan Added to Cladribine Plus Low-Dose Cytarabine in AML Patients - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/trial-launches-to-evaluate-glycomimetics-uproleselan-added-to-cladribine-plus-low-dose-cytarabine-in-aml-patients\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/trial-launches-to-evaluate-glycomimetics-uproleselan-added-to-cladribine-plus-low-dose-cytarabine-in-aml-patients\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210722005600r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","datePublished":"2021-07-22T13:03:14+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/trial-launches-to-evaluate-glycomimetics-uproleselan-added-to-cladribine-plus-low-dose-cytarabine-in-aml-patients\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/trial-launches-to-evaluate-glycomimetics-uproleselan-added-to-cladribine-plus-low-dose-cytarabine-in-aml-patients\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/trial-launches-to-evaluate-glycomimetics-uproleselan-added-to-cladribine-plus-low-dose-cytarabine-in-aml-patients\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210722005600r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210722005600r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/trial-launches-to-evaluate-glycomimetics-uproleselan-added-to-cladribine-plus-low-dose-cytarabine-in-aml-patients\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Trial Launches to Evaluate GlycoMimetics\u2019 Uproleselan Added to Cladribine Plus Low-Dose Cytarabine in AML Patients"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/516463","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=516463"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/516463\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=516463"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=516463"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=516463"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}